EUVIMEDEUVIMED entdecken
Open Access

Modulation of Abnormal Vasoconstriction Through 2‐Hydroxyisobutyrylation of Tropomyosin 3 Lys141: Targeting Histone Deacetylase 3 as a Key Approach

Pan-Pan Pang, Jiang-Xin Liu, Wen-Bin Su, Wen-Cong Gao iD, Guan-Rong Qiao, Jing Yuan, Yong-Tang Zheng iD, Chang-Bo Zheng iD

Journal of the American Heart Association · 07.01.2025 · 14 (1)

DOI: 10.1161/jaha.124.037400 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 07.01.2025. Verfasst von Pan-Pan Pang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products Kunming Medical University Kunming China. Hauptthemen laut MEDLINE: Vasoconstriction, Histone Deacetylases, Tropomyosin, Phenylephrine. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

TPM3 (tropomyosin 3) is an actin‐binding protein in vascular smooth muscle cells, where posttranslational modifications critically regulate its actin affinity, influencing cardiovascular function. Emerging evidence suggests that Khib (2‐hydroxyisobutyrylation) plays a significant role in the cardiovascular system. Histone deacetylase 3 (HDAC3) serves as an “eraser” of Khib marks. However, the impact of TPM3 de‐2‐hydroxyisobutyrylation on vascular contraction remains unclear. Methods and Results In this study, we employed mouse models and in vitro experiments to elucidate the mechanism by which phenylephrine‐induced HDAC3 activation drives vasoconstriction via de‐2‐hydroxyisobutyrylation of TPM3. Our findings demonstrate that phenylephrine triggers HDAC3 nuclear export and promotes its interaction with TPM3, resulting in decreased Khib modification and enhanced vasoconstriction. Coimmunoprecipitation experiments confirmed that phenylephrine reduces Khib levels on TPM3 in mouse aorta. Additionally, ex vivo vascular tension assays using mouse aortic rings revealed that treatment with the Khib donor, ethyl 2‐hydroxyisobutyrate, induces endothelium‐independent vasodilation and ameliorates hypertensive vascular dysfunction. Molecular docking and kinetic simulations identified Lys141 of TPM3 as the primary site targeted by HDAC3‐mediated de‐2‐hydroxyisobutyrylation. This was further validated by adenoviral transfection of isolated blood vessels with a Lys141‐mutated TPM3 construct, which abolished the effects of HDAC3 on TPM3 Khib modification and vascular contractility.

Conclusions

These findings underscore the critical role of TPM3 de‐2‐hydroxyisobutyrylation in vasoconstriction and suggest that modulating this posttranslational modification could provide a novel therapeutic strategy for hypertensive vascular dysfunction.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VasoconstrictionHistone DeacetylasesTropomyosinPhenylephrineMolecular Docking SimulationAnimalsMiceMaleMice, Inbred C57BLMuscle, Smooth, VascularDisease Models, AnimalLysineVasoconstrictor AgentsProtein Processing, Post-TranslationalHumansHistone Deacetylase 3

Stichwörter der Autor:innen

HDAC3KhibTPM3abnormal vasoconstrictioncardiovascular epigenetics

Substanzen

Histone DeacetylasesTropomyosinPhenylephrineLysineVasoconstrictor AgentsHistone Deacetylase 3

Autor:innen und Institutionen

  • School of Pharmaceutical Science and Yunnan Key Laboratory of Pharmacology for Natural Products Kunming Medical University Kunming China.
  • Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases Kunming Institute of Zoology, Chinese Academy of Sciences Kunming China.
  • State Key Laboratory of Phytochemistry and Plant Resources in West China Kunming Institute of Botany, Chinese Academy of Sciences Kunming China.
  • College of Modern Biomedical Industry Kunming Medical University Kunming China.
  • Yunnan Vaccine Laboratory Kunming China.

ORCID-Profile: Wen-Cong Gao, Yong-Tang Zheng, Chang-Bo Zheng

Zitieren

APA

Pang, P. P., Liu, J. X., Su, W. B., Gao, W. C., Qiao, G. R., Yuan, J., Zheng, Y. T., & Zheng, C. B. (2025). Modulation of Abnormal Vasoconstriction Through 2‐Hydroxyisobutyrylation of Tropomyosin 3 Lys141: Targeting Histone Deacetylase 3 as a Key Approach. Journal of the American Heart Association, 14(1). https://doi.org/10.1161/jaha.124.037400

Vancouver

Pang PP, Liu JX, Su WB, Gao WC, Qiao GR, Yuan J, et al. Modulation of Abnormal Vasoconstriction Through 2‐Hydroxyisobutyrylation of Tropomyosin 3 Lys141: Targeting Histone Deacetylase 3 as a Key Approach. Journal of the American Heart Association. 2025;14(1). doi:10.1161/jaha.124.037400

BibTeX
@article{Pang2025,
  author = {Pang, Pan-Pan and Liu, Jiang-Xin and Su, Wen-Bin and Gao, Wen-Cong and Qiao, Guan-Rong and Yuan, Jing and Zheng, Yong-Tang and Zheng, Chang-Bo},
  title = {Modulation of Abnormal Vasoconstriction Through 2‐Hydroxyisobutyrylation of Tropomyosin 3 Lys141: Targeting Histone Deacetylase 3 as a Key Approach},
  journal = {Journal of the American Heart Association},
  year = {2025},
  volume = {14},
  number = {1},
  doi = {10.1161/jaha.124.037400}
}
Kostenlos starten →